Epithelial cancers in the post-genomic era: Should we reconsider our lifestyle?

Cancer and Metastasis Reviews

Volumn 32, Issue 3-4, 2013, Pages 673-705

  Holly, Jeff M P ^a   Zeng, Li ^a   Perks, Claire M ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

Breast cancer; Colorectal cancer; Lifestyle; Metabolism; Prostate cancer

Indexed keywords

AGING; BREAST CARCINOMA; CANCER EPIDEMIOLOGY; CANCER GROWTH; CANCER INCIDENCE; CANCER RESEARCH; CARCINOMA; COLORECTAL CARCINOMA; DIABETES MELLITUS; EPIDEMIC; GENE MUTATION; HUMAN; LIFESTYLE; METABOLIC DISORDER; MUTATION RATE; OBESITY; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CARCINOMA; REVIEW;

ANIMALS; BIOLOGICAL MARKERS; CARCINOGENS; COMORBIDITY; DISEASE PROGRESSION; ENVIRONMENT; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; GENOMICS; HUMANS; LIFE STYLE; MUTATION; NEOPLASM METASTASIS; NEOPLASMS, GLANDULAR AND EPITHELIAL; PHOSPHATIDYLINOSITOL 3-KINASES; SIGNAL TRANSDUCTION;

EID: 84890316945     PISSN: 01677659     EISSN: 15737233     Source Type: Journal    
DOI: 10.1007/s10555-013-9445-5     Document Type: Review

References (275)

1. Jemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J., Murray, T., et al. (2008). Cancer statistics, 2008. CA: A Cancer Journal for Clinicians, 58, 71-96.
2. Arias, E., (2001) Deaths: Final Data for 2001. Mortality Data, NVSR, Volume 52.
3. Vogelstein, B., & Kinzler, K. W. (2004). Cancer genes and the pathways they control. Nature Medicine, 10, 789-799.
4. Talmadge, J. E., & Fidler, I. J. (2010). AACR centennial series: the biology of cancer metastasis: historical perspective. Cancer Research, 70, 5649-5669.
5. Sjoblom, T., Jones, S., Wood, L. D., Parsons, D. W., Lin, J., Barber, T. D., et al. (2006). The consensus coding sequences of human breast and colorectal cancers. Science, 314, 268-274.
6. Wood, L. D., Parsons, D. W., Jones, S., Lin, J., Sjoblom, T., Leary, R. J., et al. (2007). The genomic landscapes of human breast and colorectal cancers. Science, 318, 1108-1113.
7. Kunkel, T. A., & Bebenek, K. (2000). DNA replication fidelity. Annual Review of Biochemistry, 69, 497-529.
8. Barker, N., van Es, J. H., Kuipers, J., Kujala, P., van den Born, M., Cozijnsen, M., et al. (2007). Identification of stem cells in small intestine and colon by marker gene Lgr5. Nature, 449, 1003-1007.
9. Calabrese, P., & Shibata, D. (2010). A simple algebraic cancer equation: calculating how cancers may arise with normal mutation rates. BMC Cancer, 10, 3.
10. Wang, T. L., Rago, C., Silliman, N., Ptak, J., Markowitz, S., Willson, J. K., et al. (2002). Prevalence of somatic alterations in the colorectal cancer cell genome. Proceedings of the National Academy of Sciences of the United States of America, 99, 3076-3080.
11. Jonason, A. S., Kunala, S., Price, G. J., Restifo, R. J., Spinelli, H. M., Persing, J. A., et al. (1996). Frequent clones of p53-mutated keratinocytes in normal human skin. Proceedings of the National Academy of Sciences of the United States of America, 93, 14025-14029.
12. Martin, G. M., Ogburn, C. E., Colgin, L. M., Gown, A. M., Edland, S. D., & Monnat, R. J., Jr. (1996). Somatic mutations are frequent and increase with age in human kidney epithelial cells. Human Molecular Genetics, 5, 215-221.
13. Kwabi-Addo, B., Chung, W., Shen, L., Ittmann, M., Wheeler, T., Jelinek, J., et al. (2007). Age-related DNA methylation changes in normal human prostate tissues. Clinical Cancer Research, 13, 3796-3802.
14. Jacobs, K. B., Yeager, M., Zhou, W., Wacholder, S., Wang, Z., Rodriguez-Santiago, B., et al. (2012). Detectable clonal mosaicism and its relationship to aging and cancer. Nature Genetics, 44, 651-658.
15. Jones, S., Chen, W. D., Parmigiani, G., Diehl, F., Beerenwinkel, N., Antal, T., et al. (2008). Comparative lesion sequencing provides insights into tumor evolution. Proceedings of the National Academy of Sciences of the United States of America, 105, 4283-4288.
16. Gerlinger, M., Rowan, A. J., Horswell, S., Larkin, J., Endesfelder, D., Gronroos, E., et al. (2012). Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. The New England Journal of Medicine, 366, 883-892.
17. Navin, N., Kendall, J., Troge, J., Andrews, P., Rodgers, L., McIndoo, J., et al. (2011). Tumour evolution inferred by single-cell sequencing. Nature, 472, 90-94.
18. Ding, L., Ellis, M. J., Li, S., Larson, D. E., Chen, K., Wallis, J. W., et al. (2010). Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature, 464, 999-1005.
19. Collisson, E. A., Cho, R. J., & Gray, J. W. (2012). What are we learning from the cancer genome? Nature Reviews. Clinical Oncology, 9, 621-630.
20. Liu, W., Laitinen, S., Khan, S., Vihinen, M., Kowalski, J., Yu, G., et al. (2009). Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer. Nature Medicine, 15, 559-565.
21. Weigelt, B., & van't Veer, L. J. (2004). Hard-wired genotype in metastatic breast cancer. Cell Cycle, 3, 756-757.
22. Marusyk, A., & Polyak, K. (2013). Cancer. Cancer cell phenotypes, in fifty shades of grey. Science, 339, 528-529.
23. Kreso, A., O'Brien, C. A., van Galen, P., Gan, O. I., Notta, F., Brown, A. M., et al. (2013). Variable clonal repopulation dynamics influence chemotherapy response in colorectal cancer. Science, 339, 543-548.
24. Almendro, V., Marusyk, A., & Polyak, K. (2013). Cellular heterogeneity and molecular evolution in cancer. Annual Review of Pathology, 8, 277-302.
25. Spiller, D. G., Wood, C. D., Rand, D. A., & White, M. R. (2010). Measurement of single-cell dynamics. Nature, 465, 736-745.
26. Cohen, A. A., Geva-Zatorsky, N., Eden, E., Frenkel-Morgenstern, M., Issaeva, I., Sigal, A., et al. (2008). Dynamic proteomics of individual cancer cells in response to a drug. Science, 322, 1511-1516.
27. Chang, H. H., Hemberg, M., Barahona, M., Ingber, D. E., & Huang, S. (2008). Transcriptome-wide noise controls lineage choice in mammalian progenitor cells. Nature, 453, 544-547.
28. Brock, A., Chang, H., & Huang, S. (2009). Non-genetic heterogeneity - a mutation-independent driving force for the somatic evolution of tumours. Nature Reviews Genetics, 10, 336-342.
29. Andervont, H. B., & Dunn, T. B. (1962). Occurrence of tumors in wild house mice. Journal of the National Cancer Institute, 28, 1153-1163.
30. Newman, S. J., & Smith, S. A. (2006). Marine mammal neoplasia: a review. Veterinary Pathology, 43, 865-880.
31. Peto, R., Roe, F. J., Lee, P. N., Levy, L., & Clack, J. (1975). Cancer and ageing in mice and men. British Journal of Cancer, 32, 411-426.
32. Caulin, A. F., & Maley, C. C. (2011). Peto's Paradox: evolution's prescription for cancer prevention. Trends in Ecology & Evolution, 26, 175-182.
33. Leroi, A. M., Koufopanou, V., & Burt, A. (2003). Cancer selection. Nature Reviews. Cancer, 3, 226-231.
34. Savage, V. M., Allen, A. P., Brown, J. H., Gillooly, J. F., Herman, A. B., Woodruff, W. H., et al. (2007). Scaling of number, size, and metabolic rate of cells with body size in mammals. Proceedings of the National Academy of Sciences of the United States of America, 104, 4718-4723.
35. Turker, M. S. (1998). Estimation of mutation frequencies in normal mammalian cells and the development of cancer. Seminars in Cancer Biology, 8, 407-419.
36. Shih, C., Padhy, L. C., Murray, M., & Weinberg, R. A. (1981). Transforming genes of carcinomas and neuroblastomas introduced into mouse fibroblasts. Nature, 290, 261-264.
37. Vineis, P. (2003). Cancer as an evolutionary process at the cell level: an epidemiological perspective. Carcinogenesis, 24, 1-6.
38. Honchel, R., Halling, K. C., & Thibodeau, S. N. (1995). Genomic instability in neoplasia. Seminars in Cell Biology, 6, 45-52.
39. Fasouliotis, S. J., & Schenker, J. G. (2000). BRCA1 and BRCA2 gene mutations: decision-making dilemmas concerning testing and management. Obstetrical and Gynecological Survey, 55, 373-384.
40. Aguirre, A. J., Bardeesy, N., Sinha, M., Lopez, L., Tuveson, D. A., Horner, J., et al. (2003). Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma. Genes & Development, 17, 3112-3126.
41. Yamashita, N., Minamoto, T., Ochiai, A., Onda, M., & Esumi, H. (1995). Frequent and characteristic K-ras activation and absence of p53 protein accumulation in aberrant crypt foci of the colon. Gastroenterology, 108, 434-440.
42. Sieben, N. L., Macropoulos, P., Roemen, G. M., Kolkman-Uljee, S. M., Jan Fleuren, G., Houmadi, R., et al. (2004). In ovarian neoplasms, BRAF, but not KRAS, mutations are restricted to low-grade serous tumours. The Journal of Pathology, 202, 336-340.
43. Potter, J. D. (2007). Morphogens, morphostats, microarchitecture and malignancy. Nature Reviews. Cancer, 7, 464-474.
44. Hendrix, M. J., Seftor, E. A., Seftor, R. E., Kasemeier-Kulesa, J., Kulesa, P. M., & Postovit, L. M. (2007). Reprogramming metastatic tumour cells with embryonic microenvironments. Nature Reviews. Cancer, 7, 246-255.
45. Stoker, A. W., Hatier, C., & Bissell, M. J. (1990). The embryonic environment strongly attenuates v-src oncogenesis in mesenchymal and epithelial tissues, but not in endothelia. The Journal of Cell Biology, 111, 217-228.
46. Maffini, M. V., Calabro, J. M., Soto, A. M., & Sonnenschein, C. (2005). Stromal regulation of neoplastic development: age-dependent normalization of neoplastic mammary cells by mammary stroma. American Journal of Pathology, 167, 1405-1410.
47. Maffini, M. V., Soto, A. M., Calabro, J. M., Ucci, A. A., & Sonnenschein, C. (2004). The stroma as a crucial target in rat mammary gland carcinogenesis. Journal of Cell Science, 117, 1495-1502.
48. Barcellos-Hoff, M. H., & Ravani, S. A. (2000). Irradiated mammary gland stroma promotes the expression of tumorigenic potential by unirradiated epithelial cells. Cancer Research, 60, 1254-1260.
49. Paget, S. (1889). The distribution of secondary growths in cancer of the breast. The Lancet, I, 571-573.
50. Bissell, M. J., & Hines, W. C. (2011). Why don't we get more cancer? A proposed role of the microenvironment in restraining cancer progression. Nature Medicine, 17, 320-329.
51. Uhr, J. W., & Pantel, K. (2011). Controversies in clinical cancer dormancy. Proceedings of the National Academy of Sciences of the United States of America, 108, 12396-12400.
52. Demicheli, R., Abbattista, A., Miceli, R., Valagussa, P., & Bonadonna, G. (1996). Time distribution of the recurrence risk for breast cancer patients undergoing mastectomy: further support about the concept of tumor dormancy. Breast Cancer Research and Treatment, 41, 177-185.
53. Beerenwinkel, N., Antal, T., Dingli, D., Traulsen, A., Kinzler, K. W., Velculescu, V. E., et al. (2007). Genetic progression and the waiting time to cancer. PLoS Computational Biology, 3, e225.
54. Velculescu, V. E. (2008). Defining the blueprint of the cancer genome. Carcinogenesis, 29, 1087-1091.
55. Hanahan, D., & Weinberg, R. A. (2000). The hallmarks of cancer. Cell, 100, 57-70.
56. Hanahan, D., & Weinberg, R. A. (2011). Hallmarks of cancer: the next generation. Cell, 144, 646-674.
57. Durante, F. (1874). Nesso fisio-pathologico tra la struttura dei nei materni e la genesi di alcuni tumori maligni. Arch Memori ed Osservazioni di Chirugia Practica, 11, 217-226.
58. Dvorak, H. F. (1986). Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. The New England Journal of Medicine, 315, 1650-1659.
59. Schafer, M., & Werner, S. (2008). Cancer as an overhealing wound: an old hypothesis revisited. Nature Reviews Molecular Cell Biology, 9, 628-638.
60. Zhao, M., Song, B., Pu, J., Wada, T., Reid, B., Tai, G., et al. (2006). Electrical signals control wound healing through phosphatidylinositol-3-OH kinase-gamma and PTEN. Nature, 442, 457-460.
61. Prehn, R. T. (1997). Regeneration versus neoplastic growth. Carcinogenesis, 18, 1439-1444.
62. Oviedo, N. J., & Beane, W. S. (2009). Regeneration: the origin of cancer or a possible cure? Seminars in Cell & Developmental Biology, 20, 557-564.
63. Folkman, J., & Kalluri, R. (2004). Cancer without disease. Nature, 427, 787.
64. Welch, H. G., & Black, W. C. (1997). Using autopsy series to estimate the disease "reservoir" for ductal carcinoma in situ of the breast: how much more breast cancer can we find? Annals of Internal Medicine, 127, 1023-1028.
65. Nielsen, M., Thomsen, J. L., Primdahl, S., Dyreborg, U., & Andersen, J. A. (1987). Breast cancer and atypia among young and middle-aged women: a study of 110 medicolegal autopsies. British Journal of Cancer, 56, 814-819.
66. Renehan, A. G., Bhaskar, P., Painter, J. E., O'Dwyer, S. T., Haboubi, N., Varma, J., et al. (2000). The prevalence and characteristics of colorectal neoplasia in acromegaly. Journal of Clinical Endocrinology and Metabolism, 85, 3417-3424.
67. Anderson, J. C., Swede, H., Rustagi, T., Protiva, P., Pleau, D., Brenner, B. M., et al. (2012). Aberrant crypt foci as predictors of colorectal neoplasia on repeat colonoscopy. Cancer Causes & Control, 23, 355-361.
68. Delongchamps, N. B., Singh, A., & Haas, G. P. (2006). The role of prevalence in the diagnosis of prostate cancer. Cancer Control, 13, 158-168.
69. Sakr, W. A., Grignon, D. J., Crissman, J. D., Heilbrun, L. K., Cassin, B. J., Pontes, J. J., et al. (1994). High grade prostatic intraepithelial neoplasia (HGPIN) and prostatic adenocarcinoma between the ages of 20-69: an autopsy study of 249 cases. In Vivo, 8, 439-443.
70. Sheldon, C. A., Williams, R. D., & Fraley, E. E. (1980). Incidental carcinoma of the prostate: a review of the literature and critical reappraisal of classification. Journal of Urology, 124, 626-631.
71. Powell, I. J., Bock, C. H., Ruterbusch, J. J., & Sakr, W. (2010). Evidence supports a faster growth rate and/or earlier transformation to clinically significant prostate cancer in black than in white American men, and influences racial progression and mortality disparity. Journal of Urology, 183, 1792-1796.
72. Ries, L.A. DHS Publication no (NIH) 91-2789.
73. Thompson, I. M., Pauler, D. K., Goodman, P. J., Tangen, C. M., Lucia, M. S., Parnes, H. L., et al. (2004). Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. The New England Journal of Medicine, 350, 2239-2246.
74. Gosselaar, C., Roobol, M. J., & Schroder, F. H. (2005). Prevalence and characteristics of screen-detected prostate carcinomas at low prostate-specific antigen levels: aggressive or insignificant? BJU International, 95, 231-237.
75. Lin, K., Hsin, H., Libina, N., & Kenyon, C. (2001). Regulation of the Caenorhabditis elegans longevity protein DAF-16 by insulin/IGF-1 and germline signaling. Nature Genetics, 28, 139-145.
76. Kenyon, C. J. (2010). The genetics of ageing. Nature, 464, 504-512.
77. Byfield, M. P., Murray, J. T., & Backer, J. M. (2005). hVps34 is a nutrient-regulated lipid kinase required for activation of p70 S6 kinase. Journal of Biological Chemistry, 280, 33076-33082.
78. Chalhoub, N., & Baker, S. J. (2009). PTEN and the PI3-kinase pathway in cancer. Annual Review of Pathology, 4, 127-150.
79. Gluckman, P. D. (1997). Endocrine and nutritional regulation of prenatal growth. Acta Paediatrica. Supplementum, 423, 153-157. discussion 158.
80. Roos, D., & Loos, J. A. (1973). Changes in the carbohydrate metabolism of mitogenically stimulated human peripheral lymphocytes. II. Relative importance of glycolysis and oxidative phosphorylation on phytohaemagglutinin stimulation. Experimental Cell Research, 77, 127-135.
81. Wang, T., Marquardt, C., & Foker, J. (1976). Aerobic glycolysis during lymphocyte proliferation. Nature, 261, 702-705.
82. Hunt, T. K., Aslam, R. S., Beckert, S., Wagner, S., Ghani, Q. P., Hussain, M. Z., et al. (2007). Aerobically derived lactate stimulates revascularization and tissue repair via redox mechanisms. Antioxidants & Redox Signaling, 9, 1115-1124.
83. Newsholme, E. A., Crabtree, B., & Ardawi, M. S. (1985). The role of high rates of glycolysis and glutamine utilization in rapidly dividing cells. Bioscience Reports, 5, 393-400.
84. Cairns, R. A., Harris, I. S., & Mak, T. W. (2011). Regulation of cancer cell metabolism. Nature Reviews. Cancer, 11, 85-95.
85. Dang, C. V. (2012). Links between metabolism and cancer. Genes & Development, 26, 877-890.
86. Fiske, B. P., & Vander Heiden, M. G. (2012). Seeing the Warburg effect in the developing retina. Nature Cell Biology, 14, 790-791.
87. DeBerardinis, R. J., Lum, J. J., Hatzivassiliou, G., & Thompson, C. B. (2008). The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metabolism, 7, 11-20.
88. Elstrom, R. L., Bauer, D. E., Buzzai, M., Karnauskas, R., Harris, M. H., Plas, D. R., et al. (2004). Akt stimulates aerobic glycolysis in cancer cells. Cancer Research, 64, 3892-3899.
89. Chang, Y., Wang, J., Lu, X., Thewke, D. P., & Mason, R. J. (2005). KGF induces lipogenic genes through a PI3K and JNK/SREBP-1 pathway in H292 cells. Journal of Lipid Research, 46, 2624-2635.
90. Gingras, A. C., Raught, B., & Sonenberg, N. (2001). Regulation of translation initiation by FRAP/mTOR. Genes & Development, 15, 807-826.
91. Mazurek, S. (2011). Pyruvate kinase type M2: a key regulator of the metabolic budget system in tumor cells. The International Journal of Biochemistry & Cell Biology, 43, 969-980.
92. Christofk, H. R., Vander Heiden, M. G., Wu, N., Asara, J. M., & Cantley, L. C. (2008). Pyruvate kinase M2 is a phosphotyrosine-binding protein. Nature, 452, 181-186.
93. Christofk, H. R., Vander Heiden, M. G., Harris, M. H., Ramanathan, A., Gerszten, R. E., Wei, R., et al. (2008). The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature, 452, 230-233.
94. Bluemlein, K., Gruning, N. M., Feichtinger, R. G., Lehrach, H., Kofler, B., & Ralser, M. (2011). No evidence for a shift in pyruvate kinase PKM1 to PKM2 expression during tumorigenesis. Oncotarget, 2, 393-400.
95. Imamura, K., & Tanaka, T. (1972). Multimolecular forms of pyruvate kinase from rat and other mammalian tissues. I. Electrophoretic studies. Journal of Biochemistry, 71, 1043-1051.
96. Li, J., Yen, C., Liaw, D., Podsypanina, K., Bose, S., Wang, S. I., et al. (1997). PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science, 275, 1943-1947.
97. Bensaad, K., Tsuruta, A., Selek, M. A., Vidal, M. N., Nakano, K., Bartrons, R., et al. (2006). TIGAR, a p53-inducible regulator of glycolysis and apoptosis. Cell, 126, 107-120.
98. Matoba, S., Kang, J. G., Patino, W. D., Wragg, A., Boehm, M., Gavrilova, O., et al. (2006). p53 regulates mitochondrial respiration. Science, 312, 1650-1653.
99. Shim, H., Dolde, C., Lewis, B. C., Wu, C. S., Dang, G., Jungmann, R. A., et al. (1997). c-Myc transactivation of LDH-A: implications for tumor metabolism and growth. Proceedings of the National Academy of Sciences of the United States of America, 94, 6658-6663.
100. Dang, C. V., O'Donnell, K. A., Zeller, K. I., Nguyen, T., Osthus, R. C., & Li, F. (2006). The c-Myc target gene network. Seminars in Cancer Biology, 16, 253-264.
101. Dang, C. V. (2010). Rethinking the Warburg effect with Myc micromanaging glutamine metabolism. Cancer Research, 70, 859-862.
102. Li, F., Wang, Y., Zeller, K. I., Potter, J. J., Wonsey, D. R., O'Donnell, K. A., et al. (2005). Myc stimulates nuclearly encoded mitochondrial genes and mitochondrial biogenesis. Molecular and Cellular Biology, 25, 6225-6234.
103. Levine, A. J., & Puzio-Kuter, A. M. (2010). The control of the metabolic switch in cancers by oncogenes and tumor suppressor genes. Science, 330, 1340-1344.
104. Lichtenstein, P., Holm, N. V., Verkasalo, P. K., Iliadou, A., Kaprio, J., Koskenvuo, M., et al. (2000). Environmental and heritable factors in the causation of cancer-analyses of cohorts of twins from Sweden, Denmark, and Finland. The New England Journal of Medicine, 343, 78-85.
105. Baker, S. G., Lichtenstein, P., Kaprio, J., & Holm, N. (2005). Genetic susceptibility to prostate, breast, and colorectal cancer among Nordic twins. Biometrics, 61, 55-63.
106. Kaprio, J. (2012). Twins and the mystery of missing heritability: the contribution of gene-environment interactions. Journal of Internal Medicine, 272, 440-448.
107. Czene, K., Lichtenstein, P., & Hemminki, K. (2002). Environmental and heritable causes of cancer among 9.6 million individuals in the Swedish Family-Cancer Database. International Journal of Cancer, 99, 260-266.
108. Sorensen, T. I., Nielsen, G. G., Andersen, P. K., & Teasdale, T. W. (1988). Genetic and environmental influences on premature death in adult adoptees. The New England Journal of Medicine, 318, 727-732.
109. McCarthy, M. I., Abecasis, G. R., Cardon, L. R., Goldstein, D. B., Little, J., Ioannidis, J. P., et al. (2008). Genome-wide association studies for complex traits: consensus, uncertainty and challenges. Nature Reviews Genetics, 9, 356-369.
110. Manolio, T. A., Collins, F. S., Cox, N. J., Goldstein, D. B., Hindorff, L. A., Hunter, D. J., et al. (2009). Finding the missing heritability of complex diseases. Nature, 461, 747-753.
111. Eichler, E. E., Flint, J., Gibson, G., Kong, A., Leal, S. M., Moore, J. H., et al. (2010). Missing heritability and strategies for finding the underlying causes of complex disease. Nature Reviews Genetics, 11, 446-450.
112. Moore, J. H., & Williams, S. M. (2009). Epistasis and its implications for personal genetics. American Journal of Human Genetics, 85, 309-320.
113. Tyler, A. L., Asselbergs, F. W., Williams, S. M., & Moore, J. H. (2009). Shadows of complexity: what biological networks reveal about epistasis and pleiotropy. Bioessays, 31, 220-227.
114. Hill, W. G., Goddard, M. E., & Visscher, P. M. (2008). Data and theory point to mainly additive genetic variance for complex traits. PLoS Genetics, 4, e1000008.
115. Ciampa, J., Yeager, M., Amundadottir, L., Jacobs, K., Kraft, P., Chung, C., et al. (2011). Large-scale exploration of gene-gene interactions in prostate cancer using a multistage genome-wide association study. Cancer Research, 71, 3287-3295.
116. Milne, R. L., Gaudet, M. M., Spurdle, A. B., Fasching, P. A., Couch, F. J., Benitez, J., et al. (2010). Assessing interactions between the associations of common genetic susceptibility variants, reproductive history and body mass index with breast cancer risk in the breast cancer association consortium: a combined case-control study. Breast Cancer Research, 12, R110.
117. Broeks, A., Schmidt, M. K., Sherman, M. E., Couch, F. J., Hopper, J. L., Dite, G. S., et al. (2011). Low penetrance breast cancer susceptibility loci are associated with specific breast tumor subtypes: findings from the Breast Cancer Association Consortium. Human Molecular Genetics, 20, 3289-3303.
118. Fasching, P. A., Pharoah, P. D., Cox, A., Nevanlinna, H., Bojesen, S. E., Karn, T., et al. (2012). The role of genetic breast cancer susceptibility variants as prognostic factors. Human Molecular Genetics, 21, 3926-3939.
119. Weber, W. (2010). Cancer epigenetics. Progress in Molecular Biology and Translational Science, 95, 299-349.
120. Dawson, M. A., & Kouzarides, T. (2012). Cancer epigenetics: from mechanism to therapy. Cell, 150, 12-27.
121. You, J. S., & Jones, P. A. (2012). Cancer genetics and epigenetics: two sides of the same coin? Cancer Cell, 22, 9-20.
122. Cui, H., Cruz-Correa, M., Giardiello, F. M., Hutcheon, D. F., Kafonek, D. R., Brandenburg, S., et al. (2003). Loss of IGF2 imprinting: a potential marker of colorectal cancer risk. Science, 299, 1753-1755.
123. Bhusari, S., Yang, B., Kueck, J., Huang, W., & Jarrard, D. F. (2011). Insulin-like growth factor-2 (IGF2) loss of imprinting marks a field defect within human prostates containing cancer. Prostate, 71, 1621-1630.
124. Kaneda, A., Wang, C. J., Cheong, R., Timp, W., Onyango, P., Wen, B., et al. (2007). Enhanced sensitivity to IGF-II signaling links loss of imprinting of IGF2 to increased cell proliferation and tumor risk. Proceedings of the National Academy of Sciences of the United States of America, 104, 20926-20931.
125. Ogawa, O., Eccles, M. R., Szeto, J., McNoe, L. A., Yun, K., Maw, M. A., et al. (1993). Relaxation of insulin-like growth factor II gene imprinting implicated in Wilms' tumour. Nature, 362, 749-751.
126. DeBaun, M. R., Niemitz, E. L., McNeil, D. E., Brandenburg, S. A., Lee, M. P., & Feinberg, A. P. (2002). Epigenetic alterations of H19 and LIT1 distinguish patients with Beckwith-Wiedemann syndrome with cancer and birth defects. American Journal of Human Genetics, 70, 604-611.
127. Nicoloso, M. S., Sun, H., Spizzo, R., Kim, H., Wickramasinghe, P., Shimizu, M., et al. (2010). Single-nucleotide polymorphisms inside microRNA target sites influence tumor susceptibility. Cancer Research, 70, 2789-2798.
128. Whitelaw, N. C., & Whitelaw, E. (2008). Transgenerational epigenetic inheritance in health and disease. Current Opinion in Genetics and Development, 18, 273-279.
129. Migicovsky, Z., & Kovalchuk, I. (2011). Epigenetic memory in mammals. Frontiers in Genetics, 2, 28.
130. Sandovici, I., Leppert, M., Hawk, P. R., Suarez, A., Linares, Y., & Sapienza, C. (2003). Familial aggregation of abnormal methylation of parental alleles at the IGF2/H19 and IGF2R differentially methylated regions. Human Molecular Genetics, 12, 1569-1578.
131. Furrow, R. E., Christiansen, F. B., & Feldman, M. W. (2011). Environment-sensitive epigenetics and the heritability of complex diseases. Genetics, 189, 1377-1387.
132. Guerrero-Bosagna, C., & Skinner, M. K. (2012). Environmentally induced epigenetic transgenerational inheritance of phenotype and disease. Molecular and Cellular Endocrinology, 354, 3-8.
133. de Assis, S., Warri, A., Cruz, M. I., Laja, O., Tian, Y., Zhang, B., et al. (2012). High-fat or ethinyl-oestradiol intake during pregnancy increases mammary cancer risk in several generations of offspring. Nature Communications, 3, 1053.
134. Dunn, G. A., & Bale, T. L. (2011). Maternal high-fat diet effects on third-generation female body size via the paternal lineage. Endocrinology, 152, 2228-2236.
135. Waterland, R. A., Travisano, M., Tahiliani, K. G., Rached, M. T., & Mirza, S. (2008). Methyl donor supplementation prevents transgenerational amplification of obesity. International Journal of Obesity, 32, 1373-1379.
136. Fraga, M. F., Ballestar, E., Paz, M. F., Ropero, S., Setien, F., Ballestar, M. L., et al. (2005). Epigenetic differences arise during the lifetime of monozygotic twins. Proceedings of the National Academy of Sciences of the United States of America, 102, 10604-10609.
137. Talens, R. P., Christensen, K., Putter, H., Willemsen, G., Christiansen, L., Kremer, D., et al. (2012). Epigenetic variation during the adult lifespan: cross-sectional and longitudinal data on monozygotic twin pairs. Aging Cell, 11, 694-703.
138. Bjornsson, H. T., Sigurdsson, M. I., Fallin, M. D., Irizarry, R. A., Aspelund, T., Cui, H., et al. (2008). Intra-individual change over time in DNA methylation with familial clustering. JAMA: The Journal of the American Medical Association, 299, 2877-2883.
139. Doll, R., & Peto, R. (1981). The causes of cancer: quantitative estimates of avoidable risks of cancer in the United States today. Journal of the National Cancer Institute, 66, 1191-1308.
140. Doll, R. (1998). Epidemiological evidence of the effects of behaviour and the environment on the risk of human cancer. Recent Results in Cancer Research, 154, 3-21.
141. Bray, F., McCarron, P., & Parkin, D. M. (2004). The changing global patterns of female breast cancer incidence and mortality. Breast Cancer Research, 6, 229-239.
142. Bray, F., Ren, J. S., Masuyer, E., & Ferlay, J. (2013). Global estimates of cancer prevalence for 27 sites in the adult population in 2008. International Journal of Cancer, 132, 1133-1145.
143. Yu, H., Harris, R. E., Gao, Y. T., Gao, R., & Wynder, E. L. (1991). Comparative epidemiology of cancers of the colon, rectum, prostate and breast in Shanghai, China versus the United States. International Journal of Epidemiology, 20, 76-81.
144. Wynder, E. L., Fujita, Y., Harris, R. E., Hirayama, T., & Hiyama, T. (1991). Comparative epidemiology of cancer between the United States and Japan. A second look. Cancer, 67, 746-763.
145. Peto, J. (2001). Cancer epidemiology in the last century and the next decade. Nature, 411, 390-395.
146. McMichael, A. J., & Giles, G. G. (1988). Cancer in migrants to Australia: extending the descriptive epidemiological data. Cancer Research, 48, 751-756.
147. Ziegler, R. G., Hoover, R. N., Pike, M. C., Hildesheim, A., Nomura, A. M., West, D. W., et al. (1993). Migration patterns and breast cancer risk in Asian-American women. Journal of the National Cancer Institute, 85, 1819-1827.
148. Kolonel, L. N., Altshuler, D., & Henderson, B. E. (2004). The multiethnic cohort study: exploring genes, lifestyle and cancer risk. Nature Reviews. Cancer, 4, 519-527.
149. Watanabe, M., Nakayama, T., Shiraishi, T., Stemmermann, G. N., & Yatani, R. (2000). Comparative studies of prostate cancer in Japan versus the United States. A review. Urologic Oncology, 5, 274-283.
150. Campbell, T. C., & Chen, J. (1999). Energy balance: interpretation of data from rural China. Toxicological Sciences, 52, 87-94.
151. Tominaga, S., & Kuroishi, T. (1997). An ecological study on diet/nutrition and cancer in Japan. International Journal of Cancer. Supplement, 10, 2-6.
152. Michels, K. B., & Willett, W. C. (2004). Breast cancer - early life matters. The New England Journal of Medicine, 351, 1679-1681.
153. Sim, H. G., & Cheng, C. W. (2005). Changing demography of prostate cancer in Asia. European Journal of Cancer, 41, 834-845.
154. Shiraishi, T., Watanabe, M., Matsuura, H., Kusano, I., Yatani, R., & Stemmermann, G. N. (1994). The frequency of latent prostatic carcinoma in young males: the Japanese experience. In Vivo, 8, 445-447.
155. Yatani, R., Shiraishi, T., Nakakuki, K., Kusano, I., Takanari, H., Hayashi, T., et al. (1988). Trends in frequency of latent prostate carcinoma in Japan from 1965-1979 to 1982-1986. Journal of the National Cancer Institute, 80, 683-687.
156. Yatani, R., Chigusa, I., Akazaki, K., Stemmermann, G. N., Welsh, R. A., & Correa, P. (1982). Geographic pathology of latent prostatic carcinoma. International Journal of Cancer, 29, 611-616.
157. King, M. C., Marks, J. H., & Mandell, J. B. (2003). Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science, 302, 643-646.
158. Tryggvadottir, L., Sigvaldason, H., Olafsdottir, G. H., Jonasson, J. G., Jonsson, T., Tulinius, H., et al. (2006). Population-based study of changing breast cancer risk in Icelandic BRCA2 mutation carriers, 1920-2000. Journal of the National Cancer Institute, 98, 116-122.
159. Nkondjock, A., Robidoux, A., Paredes, Y., Narod, S. A., & Ghadirian, P. (2006). Diet, lifestyle and BRCA-related breast cancer risk among French-Canadians. Breast Cancer Research and Treatment, 98, 285-294.
160. Ghadirian, P., Narod, S., Fafard, E., Costa, M., Robidoux, A., & Nkondjock, A. (2009). Breast cancer risk in relation to the joint effect of BRCA mutations and diet diversity. Breast Cancer Research and Treatment, 117, 417-422.
161. Barker, D. J. (2004). The developmental origins of adult disease. Journal of the American College of Nutrition, 23, 588S-595S.
162. Barker, D. J., Gluckman, P. D., Godfrey, K. M., Harding, J. E., Owens, J. A., & Robinson, J. S. (1993). Fetal nutrition and cardiovascular disease in adult life. Lancet, 341, 938-941.
163. McCormack, V. A., dos Santos Silva, I., De Stavola, B. L., Mohsen, R., Leon, D. A., & Lithell, H. O. (2003). Fetal growth and subsequent risk of breast cancer: results from long term follow up of Swedish cohort. BMJ, 326, 248.
164. Tibblin, G., Eriksson, M., Cnattingius, S., & Ekbom, A. (1995). High birthweight as a predictor of prostate cancer risk. Epidemiology, 6, 423-424.
165. Sandhu, M. S., Luben, R., Day, N. E., & Khaw, K. T. (2002). Self-reported birth weight and subsequent risk of colorectal cancer. Cancer Epidemiology, Biomarkers & Prevention, 11, 935-938.
166. Gunnell, D., Okasha, M., Smith, G. D., Oliver, S. E., Sandhu, J., & Holly, J. M. (2001). Height, leg length, and cancer risk: a systematic review. Epidemiologic Reviews, 23, 313-342.
167. Stavola, B. L., Hardy, R., Kuh, D., Silva, I. S., Wadsworth, M., & Swerdlow, A. J. (2000). Birthweight, childhood growth and risk of breast cancer in a British cohort. British Journal of Cancer, 83, 964-968.
168. Lawlor, D. A., Okasha, M., Gunnell, D., Smith, G. D., & Ebrahim, S. (2003). Associations of adult measures of childhood growth with breast cancer: findings from the British Women's Heart and Health Study. British Journal of Cancer, 89, 81-87.
169. Ahlgren, M., Melbye, M., Wohlfahrt, J., & Sorensen, T. I. (2004). Growth patterns and the risk of breast cancer in women. The New England Journal of Medicine, 351, 1619-1626.
170. Ben-Shlomo, Y., Holly, J., McCarthy, A., Savage, P., Davies, D., & Davey Smith, G. (2005). Prenatal and postnatal milk supplementation and adult insulin-like growth factor I: long-term follow-up of a randomized controlled trial. Cancer Epidemiology, Biomarkers & Prevention, 14, 1336-1339.
171. Rogers, I. S., Gunnell, D., Emmett, P. M., Glynn, L. R., Dunger, D. B., & Holly, J. M. (2005). Cross-sectional associations of diet and insulin-like growth factor levels in 7- to 8-year-old children. Cancer Epidemiology, Biomarkers & Prevention, 14, 204-212.
172. Martin, R. M., Holly, J. M., Middleton, N., Davey Smith, G., & Gunnell, D. (2007). Childhood diet and insulin-like growth factors in adulthood: 65 year follow-up of the Boyd Orr Cohort. European Journal of Clinical Nutrition, 61, 1281-1292.
173. Elias, S. G., Keinan-Boker, L., Peeters, P. H., Van Gils, C. H., Kaaks, R., Grobbee, D. E., et al. (2004). Long term consequences of the 1944-1945 Dutch famine on the insulin-like growth factor axis. International Journal of Cancer, 108, 628-630.
174. Elias, S. G., Peeters, P. H., Grobbee, D. E., & van Noord, P. A. (2004). Breast cancer risk after caloric restriction during the 1944-1945 Dutch famine. Journal of the National Cancer Institute, 96, 539-546.
175. Holly, J. M., & Perks, C. M. (2012). Insulin-like growth factor physiology: what we have learned from human studies. Endocrinology and Metabolism Clinics of North America, 41, 249-263. v.
176. Fletcher, O., Gibson, L., Johnson, N., Altmann, D. R., Holly, J. M., Ashworth, A., et al. (2005). Polymorphisms and circulating levels in the insulin-like growth factor system and risk of breast cancer: a systematic review. Cancer Epidemiology, Biomarkers & Prevention, 14, 2-19.
177. Key, T. J., Appleby, P. N., Reeves, G. K., & Roddam, A. W. (2010). Insulin-like growth factor 1 (IGF1), IGF binding protein 3 (IGFBP3), and breast cancer risk: pooled individual data analysis of 17 prospective studies. The Lancet Oncology, 11, 530-542.
178. Rowlands, M. A., Gunnell, D., Harris, R., Vatten, L. J., Holly, J. M., & Martin, R. M. (2009). Circulating insulin-like growth factor peptides and prostate cancer risk: a systematic review and meta-analysis. International Journal of Cancer, 124, 2416-2429.
179. Roddam, A. W., Allen, N. E., Appleby, P., Key, T. J., Ferrucci, L., Carter, H. B., et al. (2008). Insulin-like growth factors, their binding proteins, and prostate cancer risk: analysis of individual patient data from 12 prospective studies. Annals of Internal Medicine, 149, 461-471. W483-468.
180. Chi, F., Wu, R., Zeng, Y.C., Xing, R., Liu, Y. (2012). Circulation insulin-like growth factor peptides and colorectal cancer risk: an updated systematic review and meta-analysis. Molecular Biology Reports
181. Rowlands, M. A., Holly, J. M., Gunnell, D., Donovan, J., Lane, J. A., Hamdy, F., et al. (2012). Circulating insulin-like growth factors and IGF-binding proteins in PSA-detected prostate cancer: the large case-control study ProtecT. Cancer Research, 72, 503-515.
182. Rowlands, M. A., Tilling, K., Holly, J. M., Metcalfe, C., Gunnell, D., Lane, A., et al. (2013). Insulin-like growth factors (IGFs) and IGF-binding proteins in active monitoring of localized prostate cancer: a population-based observational study. Cancer Causes & Control, 24, 39-45.
183. Rowlands, M. A., Holly, J. M., Hamdy, F., Phillips, J., Goodwin, L., Marsden, G., et al. (2012). Serum insulin-like growth factors and mortality in localised and advanced clinically detected prostate cancer. Cancer Causes & Control, 23, 347-354.
184. Yang, G., Lu, G., Jin, F., Dai, Q., Best, R., Shu, X. O., et al. (2001). Population-based, case-control study of blood C-peptide level and breast cancer risk. Cancer Epidemiology, Biomarkers & Prevention, 10, 1207-1211.
185. Pisani, P. (2008). Hyper-insulinaemia and cancer, meta-analyses of epidemiological studies. Archives of Physiology and Biochemistry, 114, 63-70.
186. Irwin, M. L., Duggan, C., Wang, C. Y., Smith, A. W., McTiernan, A., Baumgartner, R. N., et al. (2011). Fasting C-peptide levels and death resulting from all causes and breast cancer: the health, eating, activity, and lifestyle study. Journal of Clinical Oncology, 29, 47-53.
187. Neuhouser, M. L., Till, C., Kristal, A., Goodman, P., Hoque, A., Platz, E. A., et al. (2010). Finasteride modifies the relation between serum C-peptide and prostate cancer risk: results from the Prostate Cancer Prevention Trial. Cancer Prevention Research (Philadelphia, Pa.), 3, 279-289.
188. Ma, J., Li, H., Giovannucci, E., Mucci, L., Qiu, W., Nguyen, P. L., et al. (2008). Prediagnostic body-mass index, plasma C-peptide concentration, and prostate cancer-specific mortality in men with prostate cancer: a long-term survival analysis. The Lancet Oncology, 9, 1039-1047.
189. Le Marchand, L., Wang, H., Rinaldi, S., Kaaks, R., Vogt, T. M., Yokochi, L., et al. (2010). Associations of plasma C-peptide and IGFBP-1 levels with risk of colorectal adenoma in a multiethnic population. Cancer Epidemiology, Biomarkers & Prevention, 19, 1471-1477.
190. Yamaji, T., Iwasaki, M., Sasazuki, S., & Tsugane, S. (2012). Gender difference in the association of insulin and the insulin-like growth factor axis with colorectal neoplasia. International Journal of Obesity, 36, 440-447.
191. Vidal, A. C., Lund, P. K., Hoyo, C., Galanko, J., Burcal, L., Holston, R., et al. (2012). Elevated C-peptide and insulin predict increased risk of colorectal adenomas in normal mucosa. BMC Cancer, 12, 389.
192. Soubry, A., Il'yasova, D., Sedjo, R., Wang, F., Byers, T., Rosen, C., et al. (2012). Increase in circulating levels of IGF-1 and IGF-1/IGFBP-3 molar ratio over a decade is associated with colorectal adenomatous polyps. International Journal of Cancer, 131, 512-517.
193. Schoen, R. E., Weissfeld, J. L., Kuller, L. H., Thaete, F. L., Evans, R. W., Hayes, R. B., et al. (2005). Insulin-like growth factor-I and insulin are associated with the presence and advancement of adenomatous polyps. Gastroenterology, 129, 464-475.
194. Orme, S. M., McNally, R. J., Cartwright, R. A., & Belchetz, P. E. (1998). Mortality and cancer incidence in acromegaly: a retrospective cohort study. United Kingdom Acromegaly Study Group. Journal of Clinical Endocrinology and Metabolism, 83, 2730-2734.
195. Slattery, M. L., Boucher, K. M., Caan, B. J., Potter, J. D., & Ma, K. N. (1998). Eating patterns and risk of colon cancer. American Journal of Epidemiology, 148, 4-16.
196. Giovannucci, E. (2001). Insulin, insulin-like growth factors and colon cancer: a review of the evidence. Journal of Nutrition, 131, 3109S-3120S.
197. Calle, E. E., Rodriguez, C., Walker-Thurmond, K., & Thun, M. J. (2003). Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. The New England Journal of Medicine, 348, 1625-1638.
198. Stein, K. B., Snyder, C. F., Barone, B. B., Yeh, H. C., Peairs, K. S., Derr, R. L., et al. (2010). Colorectal cancer outcomes, recurrence, and complications in persons with and without diabetes mellitus: a systematic review and meta-analysis. Digestive Diseases and Sciences, 55, 1839-1851.
199. Peairs, K. S., Barone, B. B., Snyder, C. F., Yeh, H. C., Stein, K. B., Derr, R. L., et al. (2011). Diabetes mellitus and breast cancer outcomes: a systematic review and meta-analysis. Journal of Clinical Oncology, 29, 40-46.
200. Stebbing, J., Sharma, A., North, B., Athersuch, T. J., Zebrowski, A., Pchejetski, D., et al. (2012). A metabolic phenotyping approach to understanding relationships between metabolic syndrome and breast tumour responses to chemotherapy. Annals of Oncology, 23, 860-866.
201. Zeng, L., Biernacka, K. M., Holly, J. M., Jarrett, C., Morrison, A. A., Morgan, A., et al. (2010). Hyperglycaemia confers resistance to chemotherapy on breast cancer cells: the role of fatty acid synthase. Endocrine-Related Cancer, 17, 539-551.
202. Zhang, F., Yang, Y., Skrip, L., Hu, D., Wang, Y., Wong, C., et al. (2012). Diabetes mellitus and risk of prostate cancer: an updated meta-analysis based on 12 case-control and 25 cohort studies. Acta Diabetologica, 49(Suppl 1), S235-S246.
203. Pierce, B. L. (2012). Why are diabetics at reduced risk for prostate cancer? A review of the epidemiologic evidence. Urologic Oncology, 30, 735-743.
204. Snyder, C. F., Stein, K. B., Barone, B. B., Peairs, K. S., Yeh, H. C., Derr, R. L., et al. (2010). Does pre-existing diabetes affect prostate cancer prognosis? A systematic review. Prostate Cancer and Prostatic Diseases, 13, 58-64.
205. Kim, H. S., Presti, J. C., Jr., Aronson, W. J., Terris, M. K., Kane, C. J., Amling, C. L., et al. (2010). Glycemic control and prostate cancer progression: results from the SEARCH database. Prostate, 70, 1540-1546.
206. Wright, J. L., Plymate, S. R., Porter, M. P., Gore, J. L., Lin, D. W., Hu, E., et al. (2013). Hyperglycemia and prostate cancer recurrence in men treated for localized prostate cancer. Prostate Cancer and Prostatic Diseases, 16, 204-208.
207. Villarreal-Garza, C., Shaw-Dulin, R., Lara-Medina, F., Bacon, L., Rivera, D., Urzua, L., et al. (2012). Impact of diabetes and hyperglycemia on survival in advanced breast cancer patients. Experimental Diabetes Research, 2012, 732027.
208. Spano, D., Heck, C., De Antonellis, P., Christofori, G., & Zollo, M. (2012). Molecular networks that regulate cancer metastasis. Seminars in Cancer Biology, 22, 234-249.
209. Sleeman, J. P., Christofori, G., Fodde, R., Collard, J. G., Berx, G., Decraene, C., et al. (2012). Concepts of metastasis in flux: the stromal progression model. Seminars in Cancer Biology, 22, 174-186.
210. Nguyen, D. X., Bos, P. D., & Massague, J. (2009). Metastasis: from dissemination to organ-specific colonization. Nature Reviews. Cancer, 9, 274-284.
211. Meng, F., & Wu, G. (2012). The rejuvenated scenario of epithelial-mesenchymal transition (EMT) and cancer metastasis. Cancer Metastasis Reviews, 31, 455-467.
212. Thiery, J. P. (2002). Epithelial-mesenchymal transitions in tumour progression. Nature Reviews. Cancer, 2, 442-454.
213. Sleeman, J. P. (2012). The metastatic niche and stromal progression. Cancer Metastasis Reviews, 31, 429-440.
214. Kaplan, R. N., Riba, R. D., Zacharoulis, S., Bramley, A. H., Vincent, L., Costa, C., et al. (2005). VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature, 438, 820-827.
215. Hiratsuka, S., Watanabe, A., Aburatani, H., & Maru, Y. (2006). Tumour-mediated upregulation of chemoattractants and recruitment of myeloid cells predetermines lung metastasis. Nature Cell Biology, 8, 1369-1375.
216. Thiery, J. P., Acloque, H., Huang, R. Y., & Nieto, M. A. (2009). Epithelial-mesenchymal transitions in development and disease. Cell, 139, 871-890.
217. Ellis, L. M., & Fidler, I. J. (2010). Finding the tumor copycat. Therapy fails, patients don't. Nature Medicine, 16, 974-975.
218. Kimura, Y., & Sumiyoshi, M. (2007). High-fat, high-sucrose, and high-cholesterol diets accelerate tumor growth and metastasis in tumor-bearing mice. Nutrition and Cancer, 59, 207-216.
219. Phoenix, K. N., Vumbaca, F., Fox, M. M., Evans, R., & Claffey, K. P. (2010). Dietary energy availability affects primary and metastatic breast cancer and metformin efficacy. Breast Cancer Research and Treatment, 123, 333-344.
220. Llaverias, G., Danilo, C., Wang, Y., Witkiewicz, A. K., Daumer, K., Lisanti, M. P., et al. (2010). A Western-type diet accelerates tumor progression in an autochthonous mouse model of prostate cancer. American Journal of Pathology, 177, 3180-3191.
221. Nunez, N. P., Hursting, S. D., Yakar, S., Fowler, D., & Vinson, C. (2009). Obesity provides a permissive milieu in inflammation-associated carcinogenesis: analysis of insulin and IGF pathways. Methods in Molecular Biology, 512, 29-37.
222. Ferguson, R. D., Novosyadlyy, R., Fierz, Y., Alikhani, N., Sun, H., Yakar, S., et al. (2012). Hyperinsulinemia enhances c-Myc-mediated mammary tumor development and advances metastatic progression to the lung in a mouse model of type 2 diabetes. Breast Cancer Research, 14, R8.
223. Ferguson, R. D., Gallagher, E. J., Cohen, D., Tobin-Hess, A., Alikhani, N., Novosyadlyy, R., et al. (2013). Hyperinsulinemia promotes metastasis to the lung in a mouse model of Her2-mediated breast cancer. Endocrine-Related Cancer, 20, 391-401.
224. Alikhani, N., Ferguson, R. D., Novosyadlyy, R., Gallagher, E. J., Scheinman, E. J., Yakar, S., et al. (2013). Mammary tumor growth and pulmonary metastasis are enhanced in a hyperlipidemic mouse model. Oncogene, 32, 961-967.
225. Cao, H., Jin, C., Huang, D., Liu, C., Sun, D., Tan, C., et al. (2013). Changes in serum IGF-1 level and tumor VEGF expression in mice with colorectal cancer under hyperglycemic conditions. Molecular Medicine Report, 7, 1361-1365.
226. Seccareccia, E., & Brodt, P. (2012). The role of the insulin-like growth factor-I receptor in malignancy: an update. Growth Hormone & IGF Research, 22, 193-199.
227. Wu, Y., Yakar, S., Zhao, L., Hennighausen, L., & LeRoith, D. (2002). Circulating insulin-like growth factor-I levels regulate colon cancer growth and metastasis. Cancer Research, 62, 1030-1035.
228. Wu, Y., Brodt, P., Sun, H., Mejia, W., Novosyadlyy, R., Nunez, N., et al. (2010). Insulin-like growth factor-I regulates the liver microenvironment in obese mice and promotes liver metastasis. Cancer Research, 70, 57-67.
229. Price, R. S., Cavazos, D. A., De Angel, R. E., Hursting, S. D., & deGraffenried, L. A. (2012). Obesity-related systemic factors promote an invasive phenotype in prostate cancer cells. Prostate Cancer and Prostatic Diseases, 15, 135-143.
230. von Hertzen, L. C., Joensuu, H., & Haahtela, T. (2011). Microbial deprivation, inflammation and cancer. Cancer Metastasis Reviews, 30, 211-223.
231. Lin, C. C., Cheng, T. L., Tsai, W. H., Tsai, H. J., Hu, K. H., Chang, H. C., et al. (2012). Loss of the respiratory enzyme citrate synthase directly links the Warburg effect to tumor malignancy. Scientific Reports, 2, 785.
232. Kamarajugadda, S., Stemboroski, L., Cai, Q., Simpson, N. E., Nayak, S., Tan, M., et al. (2012). Glucose oxidation modulates anoikis and tumor metastasis. Molecular and Cellular Biology, 32, 1893-1907.
233. Alisson-Silva, F., Freire-de-Lima, L., Donadio, J. L., Lucena, M. C., Penha, L., Sa-Diniz, J. N., et al. (2013). Increase of o-glycosylated oncofetal fibronectin in high glucose-induced epithelial-mesenchymal transition of cultured human epithelial cells. PLoS One, 8, e60471.
234. Yu, M., Bardia, A., Wittner, B. S., Stott, S. L., Smas, M. E., Ting, D. T., et al. (2013). Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition. Science, 339, 580-584.
235. Eijkelenboom, A., & Burgering, B. M. (2013). FOXOs: signalling integrators for homeostasis maintenance. Nature Reviews Molecular Cell Biology, 14, 83-97.
236. Ross-Innes, C. S., Stark, R., Teschendorff, A. E., Holmes, K. A., Ali, H. R., Dunning, M. J., et al. (2012). Differential oestrogen receptor binding is associated with clinical outcome in breast cancer. Nature, 481, 389-393.
237. Potter, A. S., Casa, A. J., & Lee, A. V. (2012). Forkhead box A1 (FOXA1) is a key mediator of insulin-like growth factor I (IGF-I) activity. Journal of Cellular Biochemistry, 113, 110-121.
238. Duncan, S. A., Navas, M. A., Dufort, D., Rossant, J., & Stoffel, M. (1998). Regulation of a transcription factor network required for differentiation and metabolism. Science, 281, 692-695.
239. Tang, Y., Shu, G., Yuan, X., Jing, N., & Song, J. (2011). FOXA2 functions as a suppressor of tumor metastasis by inhibition of epithelial-to-mesenchymal transition in human lung cancers. Cell Research, 21, 316-326.
240. Lehner, F., Kulik, U., Klempnauer, J., & Borlak, J. (2007). The hepatocyte nuclear factor 6 (HNF6) and FOXA2 are key regulators in colorectal liver metastases. The FASEB Journal, 21, 1445-1462.
241. Bloushtain-Qimron, N., Yao, J., Snyder, E. L., Shipitsin, M., Campbell, L. L., Mani, S. A., et al. (2008). Cell type-specific DNA methylation patterns in the human breast. Proceedings of the National Academy of Sciences of the United States of America, 105, 14076-14081.
242. Polyak, K., & Weinberg, R. A. (2009). Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nature Reviews. Cancer, 9, 265-273.
243. Sizemore, S. T., & Keri, R. A. (2012). The forkhead box transcription factor FOXC1 promotes breast cancer invasion by inducing matrix metalloprotease 7 (MMP7) expression. Journal of Biological Chemistry, 287, 24631-24640.
244. Schmalhofer, O., Brabletz, S., & Brabletz, T. (2009). E-cadherin, beta-catenin, and ZEB1 in malignant progression of cancer. Cancer Metastasis Reviews, 28, 151-166.
245. Butler, T. P., & Gullino, P. M. (1975). Quantitation of cell shedding into efferent blood of mammary adenocarcinoma. Cancer Research, 35, 512-516.
246. Carroll, K. K. (1975). Experimental evidence of dietary factors and hormone-dependent cancers. Cancer Research, 35, 3374-3383.
247. Ganmaa, D., Li, X. M., Wang, J., Qin, L. Q., Wang, P. Y., & Sato, A. (2002). Incidence and mortality of testicular and prostatic cancers in relation to world dietary practices. International Journal of Cancer, 98, 262-267.
248. Michels, K. B., Mohllajee, A. P., Roset-Bahmanyar, E., Beehler, G. P., & Moysich, K. B. (2007). Diet and breast cancer: a review of the prospective observational studies. Cancer, 109, 2712-2749.
249. Alberts, D. S., Martinez, M. E., Roe, D. J., Guillen-Rodriguez, J. M., Marshall, J. R., van Leeuwen, J. B., et al. (2000). Lack of effect of a high-fiber cereal supplement on the recurrence of colorectal adenomas. Phoenix Colon Cancer Prevention Physicians' Network. The New England Journal of Medicine, 342, 1156-1162.
250. Lanza, E., Yu, B., Murphy, G., Albert, P. S., Caan, B., Marshall, J. R., et al. (2007). The polyp prevention trial continued follow-up study: no effect of a low-fat, high-fiber, high-fruit, and -vegetable diet on adenoma recurrence eight years after randomization. Cancer Epidemiology, Biomarkers & Prevention, 16, 1745-1752.
251. Cole, B. F., Baron, J. A., Sandler, R. S., Haile, R. W., Ahnen, D. J., Bresalier, R. S., et al. (2007). Folic acid for the prevention of colorectal adenomas: a randomized clinical trial. JAMA: The Journal of the American Medical Association, 297, 2351-2359.
252. Albanes, D., Heinonen, O. P., Taylor, P. R., Virtamo, J., Edwards, B. K., Rautalahti, M., et al. (1996). Alpha-Tocopherol and beta-carotene supplements and lung cancer incidence in the alpha-tocopherol, beta-carotene cancer prevention study: effects of base-line characteristics and study compliance. Journal of the National Cancer Institute, 88, 1560-1570.
253. Lippman, S. M., Klein, E. A., Goodman, P. J., Lucia, M. S., Thompson, I. M., Ford, L. G., et al. (2009). Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA: The Journal of the American Medical Association, 301, 39-51.
254. Hord, N. G., & Fenton, J. I. (2007). Context is everything: mining the normal and preneoplastic microenvironment for insights into the diet and cancer risk conundrum. Molecular Nutrition & Food Research, 51, 100-106.
255. Dunn, S. E., Kari, F. W., French, J., Leininger, J. R., Travlos, G., Wilson, R., et al. (1997). Dietary restriction reduces insulin-like growth factor I levels, which modulates apoptosis, cell proliferation, and tumor progression in p53-deficient mice. Cancer Research, 57, 4667-4672.
256. Nogueira, L. M., Lavigne, J. A., Chandramouli, G. V., Lui, H., Barrett, J. C., & Hursting, S. D. (2012). Dose-dependent effects of calorie restriction on gene expression, metabolism, and tumor progression are partially mediated by insulin-like growth factor-1. Cancer Med, 1, 275-288.
257. Kalaany, N. Y., & Sabatini, D. M. (2009). Tumours with PI3K activation are resistant to dietary restriction. Nature, 458, 725-731.
258. Willcox, B. J., Willcox, D. C., Todoriki, H., Fujiyoshi, A., Yano, K., He, Q., et al. (2007). Caloric restriction, the traditional Okinawan diet, and healthy aging: the diet of the world's longest-lived people and its potential impact on morbidity and life span. Annals of the New York Academy of Sciences, 1114, 434-455.
259. Baserga, R. (2013). The decline and fall of the IGF-I receptor. Journal of Cellular Physiology, 228, 675-679.
260. Evdokimova, V., Tognon, C. E., Benatar, T., Yang, W., Krutikov, K., Pollak, M., et al. (2012). IGFBP7 binds to the IGF-1 receptor and blocks its activation by insulin-like growth factors. Science Signaling, 5, ra92.
261. Rothwell, P. M., Fowkes, F. G., Belch, J. F., Ogawa, H., Warlow, C. P., & Meade, T. W. (2011). Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet, 377, 31-41.
262. Liao, X., Lochhead, P., Nishihara, R., Morikawa, T., Kuchiba, A., Yamauchi, M., et al. (2012). Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival. The New England Journal of Medicine, 367, 1596-1606.
263. Langley, R. E., & Rothwell, P. M. (2013). Potential biomarker for aspirin use in colorectal cancer therapy. Nature Reviews. Clinical Oncology, 10, 8-10.
264. Decensi, A., Puntoni, M., Goodwin, P., Cazzaniga, M., Gennari, A., Bonanni, B., et al. (2010). Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis. Cancer Prevention Research (Philadelphia, PA), 3, 1451-1461.
265. Pollak, M. N. (2012). Investigating metformin for cancer prevention and treatment: the end of the beginning. Cancer Discovery, 2, 778-790.
266. Dowling, R. J., Niraula, S., Stambolic, V., & Goodwin, P. J. (2012). Metformin in cancer: translational challenges. Journal of Molecular Endocrinology, 48, R31-R43.
267. Fong, D. Y., Ho, J. W., Hui, B. P., Lee, A. M., Macfarlane, D. J., Leung, S. S., et al. (2012). Physical activity for cancer survivors: meta-analysis of randomised controlled trials. BMJ, 344, e70.
268. Eheman, C., Henley, S. J., Ballard-Barbash, R., Jacobs, E. J., Schymura, M. J., Noone, A. M., et al. (2012). Annual Report to the Nation on the status of cancer, 1975-2008, featuring cancers associated with excess weight and lack of sufficient physical activity. Cancer, 118, 2338-2366.
269. Martin, B., Ji, S., Maudsley, S., & Mattson, M. P. (2010). "Control" laboratory rodents are metabolically morbid: why it matters. Proceedings of the National Academy of Sciences of the United States of America, 107, 6127-6133.
270. Seok, J., Warren, H. S., Cuenca, A. G., Mindrinos, M. N., Baker, H. V., Xu, W., et al. (2013). Genomic responses in mouse models poorly mimic human inflammatory diseases. Proceedings of the National Academy of Sciences of the United States of America, 110, 3507-3512.
271. Roberts, T. G., Jr., Goulart, B. H., Squitieri, L., Stallings, S. C., Halpern, E. F., Chabner, B. A., et al. (2004). Trends in the risks and benefits to patients with cancer participating in phase 1 clinical trials. JAMA: The Journal of the American Medical Association, 292, 2130-2140.
272. Begley, C. G., & Ellis, L. M. (2012). Drug development: raise standards for preclinical cancer research. Nature, 483, 531-533.
273. Costello, L. C., & Franklin, R. B. (2012). The genetic/metabolic transformation concept of carcinogenesis. Cancer Metastasis Reviews, 31, 123-130.
274. Anisimov, V. N., Zhukovskaya, N. V., Loktionov, A. S., Vasilyeva, I. A., Kaminskaya, E. V., & Vakhtin, Y. B. (1988). Influence of host age on lung colony forming capacity of injected rat rhabdomyosarcoma cells. Cancer Letters, 40, 77-82.
275. Veronesi, U., Marubini, E., Del Vecchio, M., Manzari, A., Andreola, S., Greco, M., et al. (1995). Local recurrences and distant metastases after conservative breast cancer treatments: partly independent events. Journal of the National Cancer Institute, 87, 19-27.